20000202
 Schering-Plough Net Rises 21%, Boosted By Sales of Claritin   The Wall Street Journal,  Feb 3, 2000  MADISON, N.J. -- Drug maker Schering-Plough Corp. reported a 21% increase in fourth-quarter earnings, helped in large part by a jump in sales of the popular allergy drug Claritin.  World-wide pharmaceuticals sales rose 13% to $2 billion, led by Claritin and the viral/cancer agent Intron. World-wide sales of Claritin climbed 14% to $573 million and combined world-wide sales of the Intron A and Rebetron combination therapy increased 37% to $297 million.   
